Novavax Inc. closed 64.57% short of its 52-week high of $17.81, which the company achieved on July 26th.

Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for ...

The newly reconstituted CDC Advisory Committee on Immunization Practices will meet this week. Packed with antivaxxers, the ...